ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Small Cell Lung Carcinoma
Cancer
Colorectal Cancer
Neoplasm Metastasis
Breast Cancer
Squamous Cell Carcinoma of Head and Neck

Lung Cancer trials near Boston, MA, USA:

Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

This research study is studying a combination of two drugs as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an E...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Gefitinib
Drug: Osimertinib

Phase 1, Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 1 other location

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osim ...

Enrolling
Metastatic Non-small Cell Lung Cancer
Drug: Osimertinib
Drug: Carboplatin

Phase 2

Memorial Sloan Kettering Cancer Center (MSK)
Memorial Sloan Kettering Cancer Center (MSK)

Boston, Massachusetts, United States and 17 other locations

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung...

Enrolling
EGFR Mutation Positive Non-small Cell Lung Cancer
EGFR Mutated Non-small Cell Lung Cancer Patients
Drug: NXP900
Drug: Osimertinib

Phase 1

Nuvectis Pharma

Boston, Massachusetts, United States and 2 other locations

Locations recently updated

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC)....

Enrolling
Small Cell Lung Cancer (SCLC)
Drug: Durvalumab 50 MG/ML

Phase 2

Alliance Foundation Trials

Boston, Massachusetts, United States and 2 other locations

Osimertinib In EGFR Mutant Lung Cancer

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR muta...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Osimertinib

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Boston, Massachusetts, United States and 1 other location

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Boston, Massachusetts, United States and 210 other locations

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...

Active, not recruiting
HER2 Mutant Non-small Cell Lung Cancer
HER2-positive Metastatic Breast Cancer
Drug: ELVN-002
Drug: Trastuzumab emtansine

Phase 1

Enliven Therapeutics

Boston, Massachusetts, United States and 38 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Boston, Massachusetts, United States and 123 other locations

U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

locally advanced or metastatic disease.In addition, HER3-DXd will be evaluated in participants with locally advanced or metastatic NSCLC whose tumors...

Active, not recruiting
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (FL-DP)
Drug: HER3-DXd (CTM-3 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Boston, Massachusetts, United States and 36 other locations

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

Phase 1, Phase 2

Dizal Pharma

Boston, Massachusetts, United States and 124 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems